BillionToOne raises $273.1 million in upsized IPO

BillionToOne Inc. (NASDAQ: BLLN), a molecular diagnostics company, completed an initial public offering of 4.6 million shares of Class A common stock at $60 per share, generating approximately $273.1 million in gross proceeds, according to a statement from law firm Gunderson Dettmer.

The shares began trading on the Nasdaq Global Select Market on November 6, 2025, with the offering expected to close on November 7, 2025.

J.P. Morgan, Piper Sandler, Jefferies and William Blair served as joint book-running managers for the offering. Stifel, Wells Fargo Securities and BTIG also acted as book-running managers.

Gunderson Dettmer represented BillionToOne through multiple financing rounds from its Series A through late-stage equity and debt private rounds before the public offering.

BillionToOne describes itself as focused on making genetic tests accessible to broader populations. The company went public during what the law firm characterized as a complex capital markets environment.

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• EG Group Is Said To Confidentially File For $1 Billion UU IPO - Bloomberg
• SK hynix files for Nasdaq IPO under ticker symbol SKHY